Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer
Status:
Completed
Trial end date:
2018-01-11
Target enrollment:
Participant gender:
Summary
The primary objective is to explore the efficacy and safety of an all oral combination of
BIBF 1120 (an inhibitor of angiogenic signalling) and metronomic cyclophosphamide in patients
with multiply-relapsed advanced ovarian cancer, who have completed a minimum of two lines of
previous chemotherapy and who for any reason are not suitable for further 'standard'
intravenous chemotherapy treatments.